Research programme: gene therapies - Rocket Pharmaceuticals

Drug Profile

Research programme: gene therapies - Rocket Pharmaceuticals

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rocket Pharmaceuticals
  • Class Antianaemics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemolytic anaemia; Immunodeficiency disorders; Osteopetrosis; Unspecified
  • Research Fanconi's anaemia

Most Recent Events

  • 12 Oct 2017 Rocket Pharmaceuticals plans a clinical trial for its AAV-based gene therapy in 2018
  • 14 Sep 2017 Early research in Fanconi's anaemia in USA (Parenteral)
  • 12 Sep 2017 Preclinical trials in Haemolytic anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top